Business Description
Turning Point Therapeutics Inc
NAICS : 325412
SIC : 2834
10628 Science Center Drive, Suite 200, San Diego, CA, USA, 92121
Description
Turning Point Therapeutics Inc is a clinical-stage biopharmaceutical company involved in designing and developing molecule, targeted oncology therapies to address limitations of existing therapies. It owns a pipeline of next-generation tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in both TKI-naive and TKI-pretreated patients. The company's lead drug candidate, repotrectinib, is being evaluated in an ongoing Phase 1/2 trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with ROS1+, NTRK+ or ALK+ advanced solid tumors.
Financial Strength
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 165.75 | |||||
Equity-to-Asset | 0.94 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | -0.02 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | 43.98 | |||||
Beneish M-Score | -18.55 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -40.7 | |||||
3-Year EPS without NRI Growth Rate | -42.5 | |||||
3-Year FCF Growth Rate | -25.7 |
Momentum Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 87.5 | |||||
9-Day RSI | 77.27 | |||||
14-Day RSI | 74.83 | |||||
6-1 Month Momentum % | 120.47 | |||||
12-1 Month Momentum % | 11.85 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 16.83 | |||||
Quick Ratio | 16.83 | |||||
Cash Ratio | 16.56 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -21.3 |
Profitability Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Operating Margin % | -34185.81 | |||||
Net Margin % | -33959.03 | |||||
ROE % | -36.23 | |||||
ROA % | -34.59 | |||||
ROIC % | -1414.45 | |||||
ROC (Joel Greenblatt) % | -3648.42 | |||||
ROCE % | -36.39 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 3800.5 | |||||
PB Ratio | 4.78 | |||||
Price-to-Tangible-Book | 4.78 | |||||
EV-to-EBIT | -8.69 | |||||
EV-to-EBITDA | -8.81 | |||||
EV-to-Revenue | 2969.04 | |||||
EV-to-Forward-Revenue | 6976.22 | |||||
EV-to-FCF | -11.38 | |||||
Price-to-Net-Current-Asset-Value | 4.85 | |||||
Price-to-Net-Cash | 4.94 | |||||
Earnings Yield (Greenblatt) % | -11.51 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Gurus Latest Trades with NAS:TPTX
Executives
EMBED
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | 1.008 | ||
EPS (TTM) ($) | -6.9 | ||
Beta | -0.31 | ||
Volatility % | 133.72 | ||
14-Day RSI | 74.83 | ||
14-Day ATR ($) | 0.525604 | ||
20-Day SMA ($) | 75.111 | ||
12-1 Month Momentum % | 11.85 | ||
52-Week Range ($) | 23.77 - 82.2 | ||
Shares Outstanding (Mil) | 50.07 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 2 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Turning Point Therapeutics Inc Filings
Document | Form | Filing Date | ||
---|---|---|---|---|
No Filing Data |